In This Article:
-
Q4 2024 Revenue: $7.5 million, up from $6.9 million in Q4 2023.
-
Full Year 2024 Revenue: $25.7 million, an 85% increase from 2023.
-
AlterG Product Revenue: $5.5 million in Q4 2024, highest since acquisition in August 2023.
-
ReWalk Product Revenue: $2.0 million in Q4 2024.
-
Gross Margin (GAAP): 24.4% in Q4 2024, down from 35.5% in Q4 2023.
-
Adjusted Gross Margin (Non-GAAP): 45.4% in Q4 2024, compared to 46.9% in Q4 2023.
-
Operating Expenses (GAAP): $17.1 million in Q4 2024, up from $8.6 million in Q4 2023.
-
Adjusted Operating Expenses (Non-GAAP): $6.7 million in Q4 2024, down from $7.0 million in Q4 2023.
-
Operating Loss (GAAP): $15.2 million in Q4 2024, compared to $6.7 million in Q4 2023.
-
Adjusted Operating Loss (Non-GAAP): $3.3 million in Q4 2024, improved from $3.8 million in Q4 2023.
-
Cash and Equivalents: $6.7 million at year-end 2024, with no debt.
-
2025 Revenue Guidance: $28 million to $30 million.
-
2025 Adjusted Gross Margin Guidance: 47% to 49%.
-
2025 Non-GAAP Operating Expenses Guidance: $22 million to $23 million.
-
2025 Non-GAAP Operating Loss Guidance: $7 million to $9 million.
Release Date: March 07, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
Lifeward Ltd (NASDAQ:LFWD) achieved record revenue of $7.5 million in Q4 2024, marking the highest quarterly revenue in the company's history.
-
The company reported an 85% increase in full-year revenue for 2024, reaching $25.7 million, demonstrating significant business scaling.
-
Lifeward Ltd (NASDAQ:LFWD) has established a Sustainable Growth Plan aimed at reducing costs and improving operating efficiency.
-
The company has expanded its distribution agreement with MYOLYN, allowing for greater market penetration, particularly in the home market.
-
Lifeward Ltd (NASDAQ:LFWD) has secured a meaningful contract with BARMER in Germany, setting a standard for providing exoskeletons.
Negative Points
-
The ReWalk sales were below expectations due to delays and attrition in Medicare cases, impacting revenue predictability.
-
GAAP gross margin decreased to 24.4% in Q4 2024 from 35.5% in Q4 2023, primarily due to restructuring charges.
-
The company recorded a $9.8 million impairment charge on intangible assets, affecting GAAP operating expenses.
-
Lifeward Ltd (NASDAQ:LFWD) received a going concern qualification from auditors, reflecting concerns about the adequacy of its balance sheet.
-
The company experienced patient attrition and deferrals in the ReWalk product line, affecting sales cycles and revenue.